Omeros Corp - Company Profile

Powered by

All the data and insights you need on Omeros Corp in one report.

$195 $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Omeros Corp Strategy Report

  • Understand Omeros Corp position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Omeros Corp: Overview

Select Item

Omeros Corp (Omeros) is a biopharmaceutical company that discovers, develops and commercializes small-molecule and protein therapeutics for large-market and orphan indications. The company’s marketed product, Omidria is a phenylephrine and ketorolac injection for use during cataract surgery or replacement of intraocular lens (IOL). The company is investigating its product candidates for the use in arthroscopic, ophthalmological, and other surgical procedures including thrombotic microangiopathies, mediated glomerulopathies, addictive and compulsive disorders among others. It is also evaluating preclinical product candidates for treatment of alternative pathway disorders, central nervous system disorders, metabolic, oncologic, musculoskeletal and other disorders. Omeros is headquartered in Seattle, Washington, the US.

 Gain a 360-degree view of Omeros Corp and make more informed decisions for your business Gain a 360-degree view of Omeros Corp and make more informed decisions for your business Find out more
Headquarters United States of America
Address 201 Elliott Avenue West, Seattle, Washington, 98119
Website www.omeros.com
Telephone 1 206 6765000
No of Employees 198
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange OMER (NASD)
EPS XYZ
Net Income (2022) XYZ -348.5% (2022 vs 2021)
Market Cap* $217.9M
Net Profit Margin (0 vs) XYZ 0.0% (2022 vs 2021)
   
* As of and is in US$
View Omeros Corp financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Omeros Corp premium industry data and analytics

70+

Pipeline Drugs

Identify which of Omeros Corp’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

50+

Clinical Trials

Determine Omeros Corp go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

40+

Catalyst Calendar

Proactively evaluate Omeros Corp’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

30+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Omeros Corp’s relevant decision makers and contact details.

8

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

7

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

2

Sales & Consensus Forecasts

Understand the current and future drug revenue for Omeros Corp and assess market opportunity for new entrants with patient population 8-year forecasts.

1

Marketed Drugs

Understand Omeros Corp’s commercialized product portfolio to stay one step ahead of the market.

Products and Services

Products Brands
Omidria: Cataract Surgery or Intraocular Lens Omidria
Pipeline Narsoplimab
Narsoplimab- Renal diseases, COVID-19
XYZ
XYZ
XYZ
Understand Omeros Corp portfolio and identify potential areas for collaboration Understand Omeros Corp portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Others In February, the company received US$200 million payment from Rayner Surgical.
2022 Regulatory Approval In July, the company announced OMS906 received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
2022 Regulatory Approval In January, the company submitted to the U.S. Food and Drug Administration (FDA) its response regarding the BLA for Narsoplimab in the treatment of HSCT-TMA.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Omeros Corp Alexion Pharmaceuticals Inc Seagen Inc Harrow Inc Akari Therapeutics Plc
Headquarters United States of America United States of America United States of America United States of America United States of America
City Seattle Boston Bothell Nashville Boston
State/Province Washington Massachusetts Washington Tennessee Massachusetts
No. of Employees 198 3,000 3,256 315 9
Entity Type Public Private Private Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Gregory A. Demopulos, M.D. Chief Executive Officer; President; Chairman Executive Board 2013 64
Michael A. Jacobsen Treasurer; Vice President - Finance; Chief Accounting Officer Senior Management 2013 64
Andreas Grauer, M.D. Chief Medical Officer Senior Management 2023 -
George A. Gaitanaris, M.D., Ph.D. Chief Scientific Officer; Vice President - Science Senior Management 2012 66
Nadia Dac Vice President; Chief Commercial Officer Senior Management 2021 53
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Omeros Corp key executives to enhance your sales strategy Gain insight into Omeros Corp key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward